Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Allogene Therapeutics Inc. (ALLO) Insider Trading Activity
Healthcare • Biotechnology • 232 employees
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Total Value
-$307,396.48
Total Shares
1,297,253
Average Trade Value
-$18,082.15
Most Active Insider
Parker Geoffrey M.
Total Activity: $120,932
Largest Single Transaction
$103,387
by Parker Geoffrey M. on Oct 21, 2024
30-Day Activity
2 Transactions
Volume: 18,442 shares
Value: $22,351
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
|
Svp, Chief Technical Officer
Officer
|
Mar 1, 2025 | 31,755 | $10,000 | 223,995 (+14.2%) | Grant | |
|
Director
|
Feb 18, 2025 | 13,313 | $32,351 | 144,316 (-9.2%) | Sale | |
|
Chief Financial Officer
Officer
|
Feb 3, 2025 | 4,361 | $7,545 | 1,301,540 (-0.3%) | Sale | |
|
EVP of Rd
Officer
|
Feb 3, 2025 | 18,832 | $32,014 | 643,135 (-2.9%) | Sale | |
|
Svp, General Counsel
Officer
|
Feb 3, 2025 | 6,404 | $10,951 | 587,848 (-1.1%) | Sale | |
|
President and CEO
Director, Officer
|
Feb 3, 2025 | 46,003 | $77,285 | 5,317,237 (-0.9%) | Sale | |
|
Chief Technical Officer
Officer
|
Feb 3, 2025 | 14,746 | $25,216 | 250,713 (-5.9%) | Sale | |
|
Director
|
Jan 24, 2025 | 369,957 | $10,000 | 2,236,816 (+16.5%) | Grant | |
|
Svp, Finance
Officer
|
Jan 24, 2025 | 36,232 | $10,000 | 137,990 (+26.3%) | Grant | |
|
Svp, General Counsel
Officer
|
Jan 24, 2025 | 144,928 | $10,000 | 594,252 (+24.4%) | Grant | |
|
EVP of Rd
Officer
|
Jan 24, 2025 | 173,913 | $10,000 | 661,967 (+26.3%) | Grant | |
|
Chief Financial Officer
Officer
|
Jan 24, 2025 | 173,913 | $10,000 | 1,305,901 (+13.3%) | Grant | |
|
President and CEO
Director, Officer
|
Jan 24, 2025 | 552,174 | $9,600 | 5,363,240 (+10.3%) | Grant | |
|
EVP of Rd
Officer
|
Jan 21, 2025 | 27,199 | $48,414 | 488,054 (-5.6%) | Sale | |
|
Director
|
Dec 9, 2024 | 9,136 | $19,916 | 157,629 (-5.8%) | Sale | |
|
Director
|
Dec 5, 2024 | 9,221 | $19,917 | 307,507 (-3.0%) | Sale | |
|
Chief Financial Officer
Officer
|
Oct 21, 2024 | 36,404 | $103,387 | 1,131,988 (-3.2%) | Payment of Exercise Price |